Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 9/20 | 0.51 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | ESRRA | P11474 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756267 | 0.85 | KIF11 (0.46) | POLQRXRARXRBRXRG | |
| SCHEMBL13349970 | 0.84 | DAO (0.51) | POLQCES2DAOIDO1PDE2A | |
| SCHEMBL12593467 | 0.83 | CES2 (0.50) | POLQCES2DAOIDO1PDE2A | |
| SCHEMBL3278364 | 0.83 | CES2 (0.50) | POLQCES2DAOIDO1RXRA | |
| SCHEMBL1538523 | 0.83 | DAO (0.49) | POLQCES2DAOIDO1RXRA | |
| SCHEMBL15133743 | 0.83 | ESR1 (0.44) | POLQCES2DAOIDO1PDE2A | |
| SCHEMBL12603811 | 0.81 | DAO (0.51) | POLQCES2DAOIDO1PDE2A | |
| SCHEMBL1993639 | 0.81 | CES2 (0.52) | POLQCES2DAOIDO1PTGDR2 | |
| SCHEMBL13644756 | 0.80 | POLQ (0.46) | POLQCES2DAOIDO1PDE2A | |
| SCHEMBL18377965 | 0.80 | DAO (0.55) | POLQCES2DAOIDO1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299354-B1 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-22 | — | — | EP | claimed |
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230137110-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE THEREOF | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230026428-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-11466026-B2 | Organic electroluminescent materials and devices | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2022-10-11 | — | — | US | disclosed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| WO-2022001767-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | 武汉朗来科技发展有限公司 | 2022-01-06 | — | — | WO | disclosed |
| EP-3532486-B1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-22 | — | — | EP | disclosed |
| US-10961260-B2 | Nitrogenous compound and color conversion film comprising same | LG CHEM, LTD. (KR) | 2021-03-30 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| EP-1761529-B1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| US-7244847-B2 | Benzimidazole compounds | ISIS PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244847-B2 | Benzimidazole compounds | ISIS PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2007068418-A1 | USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-6743790-B2 | A UREA OR THIOUREA DERIVATIVES CONTAINING AMIDE GROUP USEFUL AS ANTICOAGULANTS AND ANTIINFLAMMATORY AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| EP-1299354-A2 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | Aventis Pharma Deutschland GmbH (DE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2001094301-A2 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | POLQ 4649/4885CES2 4555/4885DAO 1266/4885 |
| US-11466026-B2 | Organic electroluminescent materials and devices | OCIAD1, OCIAD2, SLCO4C1 | POLQ 1383/4885CES2 890/4885DAO 3273/4885 |
| US-20230137110-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE THEREOF | SLCO2B1, SLCO2A1, SLCO1B3 | POLQ 1920/4885CES2 1235/4885DAO 117/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | POLQ 1221/4885CES2 62/4885DAO 538/4885 |
| US-10961260-B2 | Nitrogenous compound and color conversion film comprising same | NUDC, MYB, NOTCH4 | POLQ 3543/4885CES2 2357/4885DAO 490/4885 |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | TBXA2R, HTR2C, NPY1R | POLQ 3856/4885CES2 512/4885DAO 285/4885 |
| US-20230026428-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, SLCO4C1 | POLQ 1383/4885CES2 890/4885DAO 3273/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | POLQ 1106/4885CES2 3429/4885DAO 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.